FDA Approves Jivi for Pediatric Patients Aged 7 to 12 Years With Hemophilia A

I’m still looking for a factor product that works for me

Plan D. That’s what I’m working on now. Last week, I learned that a factor VIII (FVIII) product I’m taking for my hemophilia has had some disappointing results. I can’t say I’m surprised about that, as I had a negative reaction to the medication, including feeling lightheaded and fatigued for days. While I suspected the FVIII from my plan C didn’t work, I’d really hoped I was wrong. The first and only dose I took was used to test the product’s h…

FDA Extends Approval of Jivi to Younger Hemophilia A Patients

Bayer’s Jivi is a factor VIII replacement therapy that has been engineered with a compound that allows for less frequent dosing. It is now indicated for patients 7 years of age and older.

FDA Approves Jivi for Pediatric Patients Aged 7 to 12 Years With Hemophilia A

The FDA previously approved Jivi in 2018 to treat adults aged 12 years and older with hemophilia A.